Older and high-risk populations can now receive Pfizer vaccine booster dose, FDA says

USA – People above 65 years and adults at high risk of severe COVID-19 infection are now eligible to receive Pfizer/BioNTech’s booster dose vaccine, following emergency use authorization by the Food and Drug Administration (FDA). The decision paves the way for millions of people who received their second dose of the vaccine at least six months ago to receive booster shots as soon as they can. This emergency use authorization was based on the totality of scientific evidence shared by the companies and reviewed by the FDA’s Vaccines and Related…

Read More

Pfizer/BioNTech say data shows COVID-19 vaccine safe and protective in kids

USA – Pfizer Inc and BioNTech SE have said their COVID-19 vaccine induced a robust immune response in 5 to 11-year-olds, and they plan to ask for authorization to use the vaccine in children in that age range in the United States, Europe, and elsewhere as soon as possible. The companies said the vaccine generated an immune response in the 5-to-11-year-olds in their Phase II/III clinical trial that matched what they had previously observed in 16-to-25-year-olds. The safety profile was also generally comparable to the older age group, they said.…

Read More

India repudiates Covishield supplies to COVAX as BioNTech seeks vaccine approval for kids

INDIA – India has decided not to share Covid vaccines with the rest of the world through the international vaccine alliance spearheaded by the World Health Organization and Gavi, Covax, till all the adults are immunized in the country. In March, India imposed a hold on all major exports of Covid vaccines affecting deliveries to the Covax facility and slowing down vaccination exercises in Africa. Yet, last month, COVAX had raised hopes that the Asian country would soon resume supply of locally manufactured Covid-19 vaccines as the country experienced rising…

Read More

BioNTech looking to take vaccine production know-how to Africa

AFRICA – BioNTech, now a global household name thanks to its work to produce the first COVID-19 vaccine to win full approval from the U.S. FDA, wants to take its know-how to Africa and manufacture vaccines for a host of other diseases that are also affecting local populations on the continent, most notably malaria and tuberculosis. The German company said it was examining the establishment of sustainable production facilities in Rwanda and Senegal. “Our goal is to develop vaccines in Africa and to establish sustainable production capacities for vaccines in…

Read More

GSK-made malaria vaccine could save millions of children in Africa

AFRICA – A “game-changing” malaria vaccine developed by British researchers is poised to save the lives of millions of children in Africa after trial results beat all expectations. The jab, developed by the Brentford-based pharmaceutical company GSK, was found to reduce the rate of severe malaria by 70% in a study involving nearly 6,000 children aged between five and 17 months in Burkina Faso and Mali. However, the medical cocktail must be taken in the run-up to the rainy season. Malaria mainly affects children and young people, killing more than…

Read More

Pfizer/BioNTech COVID-19 vaccine set to receive full US FDA approval

USA – The U.S. Food and Drug Administration has made public its aim to give full approval to Pfizer’s COVID-19 vaccine this coming week.   Previously, the regulator had set a deadline for September sixth, during which they would give the approval. This approval could boost the vaccination campaign by convincing more unvaccinated Americans that Pfizer’s shot is safe and effective and also make local officials more comfortable in implementing vaccine mandates. The U.S. military is expected to require that service members get vaccinated soon after Pfizer’s shot is authorized…

Read More

BioNTech to channel COVID-19 profits toward developing new Malaria and TB shots in Africa

AFRICA – BioNTech, a Covid-19 vaccine pioneer has said it will invest some of its profits from the Covid-19 vaccine it markets with Pfizer Inc. into developing shots for malaria and tuberculosis in Africa. This is part of the German based biotechnology giant plan to establish a large production hub for innovative medicines on the continent. The firm plans to build a factory in Africa and develop a manufacturing network with local partners to transfer its technology based on messenger RNA, a genetic molecule, to a continent that has suffered…

Read More

Pfizer/BioNTech strike COVID-19 vaccine manufacturing deal with Biovac South Africa

SOUTH AFRICA – Pfizer Inc and BioNTech have entered into a deal with South Africa’s Biovac Institute to process and distribute over 100 million doses a year of their COVID-19 vaccine for the African Union starting 2022. Biovac, a public-private partnership focused on vaccine production, will receive COVID-19 vaccine drug substance made in plants in Europe, and will begin so-called fill-finish operations, the last stage of drug manufacturing and packaging, in 2022. The deal, under which the Cape Town-based Biovac Institute will fill vials of the Pfizer/BioNTech vaccine and ready…

Read More

National institute of health believe mRNA vaccines can protect patients against COVID-19 for longer periods

US – According to the new study published in the Nature journal, people who received mRNA vaccines of Pfizer-BioNTech are more likely to be protected form the corona virus for longer periods than it was previously anticipated. The study was conducted by a National institute of Health supported research team led by Jackson Turner, Jane O’Halloran, Rachel Presti, and Ali Ellebedy at Washington University School of Medicine, St. Louis. Based on the research team findings, the immune systems of individuals who received Pfizer-BioNTech vaccines exhibited robustness and persistence that the…

Read More

Pfizer and BioNTech seek approval for a third jab meant to improve the vaccine’s efficacy

WORLD – Pfizer and BioNtech are planning to have their third COVID-19 vaccine jab approved for use in the US and the European Union. Both companies strongly believe that the third jab will improve the vaccines efficacy rate and could potentially boost individuals against contagious variants. The move comes amid fears that the delta variant is behind the latest outbreaks in Asia and Africa and rising cases in Europe and the US which scientists currently have discovered how it evades the human immune system. According to a new study published…

Read More